Abstracts Archive - Page 602 of 2425 - ACR Meeting Abstracts

Abstract Number: 0754 • ACR Convergence 2021
Bridging the Gap Between Patient-Reported Outcomes and Disease-Related Outcomes in Lupus – a Feasibility Study
Shivani Garg¹ and Christie Bartels², ¹UW Madison, Madison, WI, ²University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with SLE have significantly worse health-related quality of life (QOL) at an earlier age compared to patients with other chronic diseases. This highlights…
Abstract Number: 0756 • ACR Convergence 2021
Validation of Two Simple Patient-centered Outcome Measures for Virtual Monitoring of Patients with Idiopathic Inflammatory Myositis
R Naveen¹, Darpan R Thakare², Vikas Agarwal², Rohit Aggarwal³ and Latika Gupta¹, ¹Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Changing landscape of patient care from in-person to virtual telemedicine-based consultation in times of a global pandemic has necessitated a wider use of patient-centered…
Abstract Number: 0755 • ACR Convergence 2021
Satisfaction with the Process versus Outcome of Care in Total Hip and Knee Arthroplasty
J. Alex Gibbons¹, Cynthia Kahlenberg¹, Bella Mehta², Vinicius Antao¹, Emily Ying Lai¹, Huong Do¹, Linda Russell¹, Peter Sculco¹, Mark Figgie¹ and Susan Goodman¹, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Patient satisfaction, both with the process of care and the outcome of care, is critical for measuring the quality and value of elective procedures…
Abstract Number: 0751 • ACR Convergence 2021
Are Current Patient Reported Outcomes Instruments Optimized to Capture the Entire Patient Experience?
Philip Mease¹, Vibeke Strand², Dan Furst³, Evan Siegel⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Stanford University School of Medicine, Portola Valley, CA, ³University of California Los Angeles, Los Angeles, CA, ⁴Arthritis and Rheumatism Associates, Potomac, MD, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Psoriatic Arthritis (PsA) affects multiple attributes of patient health; to assess treatment effectiveness a compilation of Patient Reported Outcomes (PRO) have been utilized. While…
Abstract Number: 0745 • ACR Convergence 2021
Patient-reported Outcomes and Safety Measures in Patients with Rheumatic Diseases Who Switched from Reference or Other Biosimilar Etanercept to Biosimilar Etanercept GP2015 and in Biologic-naïve Patients Starting a Treatment with GP2015: 12-month Interim Analysis from a Real-world Study
Ayman Askari¹, Marc Schmalzing², Slawomir Jeka³, Javier De Toro Santos⁴, Eduardo Collantes-Estevez⁵, Fabricio Furlan⁶, Sohaib Hachaichi⁶ and Herbert Kellner⁷, ¹The Robert Jones and Agnes Hunt Orthopaedic Hospital, Shropshire, United Kingdom, ²Rheumatology/Clinical Immunology, Department of Internal Medicine II, University of Wuerzburg, Wuerzburg, Germany, ³Clinic and Department of Rheumatology and Connective Tissue Diseases, University Hospital No 2 in Bydgoszcz Collegium Medicum UMK in Toruń, Bydgoszcz, Poland, ⁴University Hospital Coruña, Servicio de Reumatología, A Coruña, Galicia, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Córdoba, Córdoba, Spain, ⁶Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁷Hospital Neuwittelsbach, Center for Rheumatology and Gastroenterology, Munich, Germany, Munich, Germany
Background/Purpose: GP2015 is a biosimilar of etanercept (ETN). COMPACT is an ongoing, non-interventional study, evaluating the effectiveness, safety, and quality of life with GP2015 treatment…
Abstract Number: 0726 • ACR Convergence 2021
Joint Safety of Tanezumab versus NSAIDs; A Combined Assessment of Benefit and Harm
Robert Fountaine¹, Robert Dworkin², Anne Hickman¹, Glenn Pixton³, Ed Whalen⁴, Christine West¹ and Kenneth Verburg¹, ¹Pfizer Inc., Groton, CT, ²University of Rochester, Rochester, NY, ³Pfizer Inc., Morrisville, NC, ⁴Pfizer Inc., New York, NY
Background/Purpose: Tanezumab, a monoclonal antibody against nerve growth factor, is in development for the relief of signs and symptoms of moderate to severe osteoarthritis (OA)…
Abstract Number: 0697 • ACR Convergence 2021
Detection of Autoantibodies Against Muscle-Specific Four-and-a-Half-LIM Domain 1 (FHL1) in Inflammatory Myopathies: Results from a Single-Center Cohort
Angeles Shunashy Galindo-Feria¹, Begum Horuluoglu¹, Jessica Day², Catia Cerqueira³, Edvard Wigren⁴, Susanne Gräslund⁴, Susanna Proudman⁵, Ingrid E Lundberg⁴ and Vidya Limaye⁶, ¹Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ²Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia and Discipline of Medicine, University of Adelaide, Adelaide, Australia, ³4Dcell, Montreuil, France, ⁴Karolinska Institutet, Karolinska University Hospital, Division of Rheumatology, Department of Medicine Solna, Stockholm, Sweden, Stockholm, Sweden, ⁵University of Adelaide, Medindie, Australia, ⁶Royal Adelaide Hospital, Adelaide, Australia
Background/Purpose: Autoantibodies targeting a muscle-specific autoantigen, four-and-a-half-LIM-domain 1 (FHL1), have been previously identified in patients with idiopathic inflammatory myopathies (IIM) (1). The aim of this…
Abstract Number: 0634 • ACR Convergence 2021
Correlation Between the Functional Component of the Multidimensional Health Assessment Questionnaire (FN), Modified Health Assessment Questionnaire (MHAQ), Health Assessment Questionnaire II (HAQ-II) and a Single Functional Question (PF) in Patients with Rheumatic Disease
Andrea Healy¹, Johny Fares¹, Martin Bergman², Kaleb Michaud³, Alison Petro³ and Harlan Sayles³, ¹Main Line Health, Wynnewood, PA, ²Martin Jan Bergman, MD, Ridley Park, PA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: There has been significant work developing questionnaires to find effective and reliable ways of characterizing the functional status of patients, to track disease progression…
Abstract Number: 0509 • ACR Convergence 2021
Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors
Anjaneya Chimalakonda¹, James Burke¹, Lihong Cheng¹, Ian Catlett¹, Michael Tagen¹, Qihong Zhao¹, Aditya Patel¹, Jun Shen¹, Ihab Girgis¹, Subhashis Banerjee¹ and John Throup², ¹Bristol Myers Squibb, Princeton, NJ, ²Bristol Myers Squibb, Princeton
Background/Purpose: Deucravacitinib is a novel, oral, allosteric agent that selectively inhibits intracellular signaling by binding to the tyrosine kinase 2 (TYK2) pseudokinase domain rather than…
Abstract Number: 0250 • ACR Convergence 2021
Is There a Need for a New Classification Criteria in Juvenile Spondyloarthritis?
Maria Martha Katsicas¹, Maria Cecilia Bertinotti² and Maria Giselle Villarreal², ¹Hospital de Pediatria J.P Garrahan, Buenos Aires, Argentina, ²Garrahan, Buenos Aires, Argentina
Background/Purpose: Juvenile SpA (JSpA) involve enthesitis related arthritis (ERA), juvenile psoriatic arthritis and undifferentiated arthritis (UA) according to the ILAR criteria. Two different patterns have…
Abstract Number: 1514 • ACR Convergence 2021
Age-related Metabolic Reprogramming of Memory CD4+ T Cells Is Associated with Reactive Oxygen Species-induced Immune Cell Dysfunction
Yuling Chen¹, Pierre-Louis Krau², Pelle Löwe³, Moritz Pfeiffenberger⁴, Lisa Ehlers³, Alexandra Damerau⁴, Paula Hoff³, Frank Buttgereit⁵ and Timo Gaber⁴, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charit Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Inflamm-aging is a sterile, low-grade, chronic systemic inflammatory state characterized by an increase in proinflammatory cytokines involved in the development of most age-related diseases…
Abstract Number: 1518 • ACR Convergence 2021
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Pankti Reid¹, David Liew², Rajshi Akruwala³, Anne Bass⁴ and Karmela Kim Chan⁵, ¹University of Chicago Medical Center, Chicago, IL, ²Austin Health, Heidelberg, Australia, ³SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
Abstract Number: 1522 • ACR Convergence 2021
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Anu Desai¹, Lakshmi Priya Shadananan¹, Adam Croft², Lalit Pallan¹, Neil Steven³ and Benjamin Fisher⁴, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Halesowen, United Kingdom, ³Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
Abstract Number: 1521 • ACR Convergence 2021
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Nilasha Ghosh¹, Chengsong Zhu², Karmela Kim Chan³, Michael Postow⁴ and Anne Bass⁵, ¹Hospital for Special Surgery, New York, NY, ²UT Southwestern, Dallas, TX, ³Hospital for Special Surgery, New York, NY, ⁴Memorial Sloane Kettering Cancer Center, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 1525 • ACR Convergence 2021
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Marthe Brun¹, Guro Goll¹, Kristin Jørgensen², Joseph Sexton¹, Johanna Gehin³, Øystein Sandanger⁴, Inge Olsen⁴, Rolf Anton Klaasen⁴, David Warren⁴, Cato Mørk⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad⁴, Espen Haavardsholm¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Lillehammer, Nepal, ⁴Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].